AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, previewed his presentation on atopic dermatitis and diet, before the 2025 AAD meeting.

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.

By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.

Two posters at AAD 2025 highlighted different challenges of managing patients with HS.

AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.

More than half (55.4%) of roflumilast-treated patients achieved a score of 0 or 1 vs 19.8% in the vehicle group on the Worst Itch-NRS numeric rating scale.

Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.